Show simple item record

dc.contributor.authorGlynn, D
dc.contributor.authorBliss, J
dc.contributor.authorBrunt, AM
dc.contributor.authorColes, CE
dc.contributor.authorWheatley, D
dc.contributor.authorHaviland, JS
dc.contributor.authorKirby, AM
dc.contributor.authorLongo, F
dc.contributor.authorFaria, R
dc.contributor.authorYarnold, JR
dc.contributor.authorGriffin, S
dc.identifier.citationBreast Cancer Research and Treatment, 2022,
dc.description.abstractPURPOSE: We estimated the cost-effectiveness of 4 radiotherapy modalities to treat early breast cancer in the UK. In a subgroup of patients eligible for all modalities, we compared whole-breast (WB) and partial breast (PB) radiotherapy delivered in either 15 (WB15F, PB15F) or 5 fractions (WB5F, PB5F). In a subgroup ineligible for PB radiotherapy, we compared WB15F to WB5F. METHODS: We developed a Markov cohort model to simulate lifetime healthcare costs and quality-adjusted life years (QALYs) for each modality. This was informed by the clinical analysis of two non-inferiority trials (FAST Forward and IMPORT LOW) and supplemented with external literature. The primary analysis assumed that radiotherapy modality influences health only through its impact on locoregional recurrence and radiotherapy-related adverse events. RESULTS: In the primary analysis, PB5F had the least cost and greatest expected QALYs. WB5F had the least cost and the greatest expected QALYs in those only eligible for WB radiotherapy. Applying a cost-effectiveness threshold of £15,000/QALY, there was a 62% chance that PB5F was the cost-effective alternative in the PB eligible group, and there was a 100% chance that WB5F was cost-effective in the subgroup ineligible for PB radiotherapy. CONCLUSIONS: Hypofractionation to 5 fractions and partial breast radiotherapy modalities offer potentially important benefits to the UK health system.
dc.relation.ispartofBreast Cancer Research and Treatment
dc.titleCost-effectiveness of 5 fraction and partial breast radiotherapy for early breast cancer in the UK: model-based multi-trial analysis.
dc.typeJournal Article
rioxxterms.typeJournal Article/Review
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit
pubs.publication-statusPublished online
icr.researchteamClin Trials & Stats Unit
dc.contributor.icrauthorBliss, Judith
dc.contributor.icrauthorYarnold, John
icr.provenanceDeposited by Mrs Jessica Perry (impersonating Prof Judith Bliss) on 2022-11-22. Deposit type is initial. No. of files: 1. Files: HE paper published version - breast cancer research and treatment Nov 2022.pdf

Files in this item


This item appears in the following collection(s)

Show simple item record
Except where otherwise noted, this item's license is described as